Stay updated on Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial
Sign up to get notified when there's something new on the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.

Latest updates to the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page
- Check4 days agoChange DetectedThe page now renders a 403 Forbidden error instead of the study record, indicating access is denied to this entry. The page shows a minimal header, a 403 message, and a Home button.SummaryDifference20%

- Check11 days agoChange DetectedA new revision tag v3.7.0 is now shown, replacing the previous v3.6.6, indicating an updated version of the page content.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedRevision label updated to v3.6.6, indicating a small backend/content-management update.SummaryDifference0.1%

- Check46 days agoChange DetectedThe page revision label changed from v3.6.4 to v3.6.5, indicating a small maintenance update to the page.SummaryDifference0.0%

- Check60 days agoChange DetectedThe page revision was updated from v3.6.3 to v3.6.4, indicating a minor update to the page's content or layout.SummaryDifference0.0%

- Check89 days agoChange DetectedRevision v3.6.3 was added to replace the previous v3.6.0, indicating an updated document version for the study documentation.SummaryDifference0.0%

Stay in the know with updates to Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.